Suppr超能文献

新辅助序贯靶向治疗和化疗用于Ⅲ期非小细胞肺癌的长期成功结局:10例系列报道

Successful long-term outcome of neoadjuvant sequential targeted therapy and chemotherapy for stage III non-small cell lung carcinoma: 10 case series.

作者信息

Aoki Masaya, Miyata Ryo, Kamimura Go, Morizono Shoichiro, Tokunaga Takuya, Harada-Takeda Aya, Maeda Koki, Nagata Toshiyuki, Ueda Kazuhiro

机构信息

Department of General Thoracic Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

出版信息

Transl Lung Cancer Res. 2024 Dec 31;13(12):3278-3288. doi: 10.21037/tlcr-24-545. Epub 2024 Dec 27.

Abstract

BACKGROUND

Perioperative treatment of locally advanced non-small cell lung cancer (NSCLC) is attracting attention. The effect of neoadjuvant tyrosine kinase inhibitor (TKI) therapy on postoperative long-term outcomes in patients with driver gene mutations remains unclear. The aim of this study was to clarify the long-term survival outcomes of patients with stage III NSCLC harboring driver gene mutations who received preoperative TKI therapy.

METHODS

Between January 2016 and December 2018, 10 patients with clinical stage III NSCLC with driver gene mutations were treated with TKIs [epidermal growth factor receptor () mutation, n=9; anaplastic lymphoma kinase () fusion, n=1]. One patient refused surgery. The remaining nine patients received sequential chemotherapy followed by surgery. Postoperatively, six patients received adjuvant chemotherapy, and TKIs were readministered in four patients.

RESULTS

The main adverse events of TKIs were grade 3 liver damage and grade 3 skin rash, which required a change in the drug from gefitinib to afatinib and dose reduction, respectively. In all 10 patients, the radiological response to TKIs was greater than the partial response, and nine patients underwent radical surgery. Although viable cancer cells remained in all patients with mutations, a pathological complete response was obtained in the patient with fusion. No mortality or major morbidity was observed perioperatively. Of the patients who underwent surgery, 3 were alive without recurrence, while 6 had distant metastasis, including 5 with brain metastasis. Seven of the nine patients who underwent surgery were still alive after a median follow-up period of 77.2 months.

CONCLUSIONS

Successful long-term outcomes were achieved after sequential targeted therapy and chemotherapy, followed by surgery for stage III NSCLC. However, it is noteworthy that postoperative treatment may have also contributed to minimizing postoperative recurrence.

摘要

背景

局部晚期非小细胞肺癌(NSCLC)的围手术期治疗备受关注。新辅助酪氨酸激酶抑制剂(TKI)治疗对驱动基因突变患者术后长期结局的影响尚不清楚。本研究的目的是阐明接受术前TKI治疗的III期NSCLC驱动基因突变患者的长期生存结局。

方法

2016年1月至2018年12月期间,10例临床III期NSCLC驱动基因突变患者接受了TKI治疗[表皮生长因子受体(EGFR)突变,n = 9;间变性淋巴瘤激酶(ALK)融合,n = 1]。1例患者拒绝手术。其余9例患者接受序贯化疗后进行手术。术后,6例患者接受辅助化疗,4例患者再次使用TKI。

结果

TKI的主要不良事件为3级肝损伤和3级皮疹,分别需要将药物从吉非替尼改为阿法替尼和减少剂量。在所有10例患者中,TKI的放射学反应大于部分缓解,9例患者接受了根治性手术。虽然所有EGFR突变患者中均残留有存活的癌细胞,但ALK融合患者获得了病理完全缓解。围手术期未观察到死亡或严重并发症。接受手术的患者中,3例存活无复发,6例发生远处转移,包括5例脑转移。9例接受手术的患者中,7例在中位随访77.2个月后仍存活。

结论

III期NSCLC患者经序贯靶向治疗和化疗后成功实现长期生存结局,随后进行手术。然而,值得注意的是,术后治疗也可能有助于最大限度地减少术后复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/878d/11736588/e523a5732b70/tlcr-13-12-3278-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验